Duchenne Muscular Dystrophy Therapeutics
1. Agamree patent expiration
Treatment: Treatment of duchenne muscular dystrophy
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12201639 | CATALYST PHARMS | Aqueous oral pharmaceutical suspension compositions |
Mar, 2040
(14 years from now) | |
| US11382922 | CATALYST PHARMS | Aqueous oral pharmaceutical suspension compositions |
Jul, 2040
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11690853 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-κβ for treatment of disease |
Mar, 2033
(7 years from now) | |
| US11471471 | CATALYST PHARMS | Aqueous oral pharmaceutical suspension compositions |
Mar, 2040
(14 years from now) | |
| US10857161 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-kB for treatment of disease |
May, 2029
(3 years from now) | |
| US8334279 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-κB for treatment of disease |
May, 2029
(3 years from now) | |
| US11833159 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-kB for treatment of disease |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 26, 2028 |
| Orphan Drug Exclusivity(ODE-450) | Oct 26, 2030 |
Drugs and Companies using VAMOROLONE ingredient
NCE-1 date: 27 October, 2027
Market Authorisation Date: 26 October, 2023
Dosage: SUSPENSION
More Information on Dosage
AGAMREE family patents
2. Amondys 45 patent expiration
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by resto...
AMONDYS 45's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8524880 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Apr, 2026
(2 months from now) | |
| US9416361 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| USRE48960 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Feb, 2029
(3 years from now) | |
| US10287586 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(4 years from now) | |
| US9447415 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US9228187 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10533174 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US9758783 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(4 years from now) | |
| US10781450 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2026 |
| Orphan Drug Exclusivity(ODE-347) | Feb 25, 2028 |
Drugs and Companies using CASIMERSEN ingredient
NCE-1 date: 25 February, 2025
Market Authorisation Date: 25 February, 2021
Dosage: SOLUTION
More Information on Dosage
AMONDYS 45 family patents
3. Duvyzat patent
expiration
Treatment: A method for the treatment of duchenne muscular dystrophy (dmd) using givinostat
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7329689 | ITALFARMACO SPA | Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester |
Jan, 2026
(6 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9421184 | ITALFARMACO SPA | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
Feb, 2032
(6 years from now) | |
| US9867799 | ITALFARMACO SPA | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
Feb, 2032
(6 years from now) | |
| US10688047 | ITALFARMACO SPA | Physically and chemically stable oral suspensions of givinostat |
Oct, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2029 |
| Orphan Drug Exclusivity(ODE-473) | Mar 21, 2031 |
Drugs and Companies using GIVINOSTAT HYDROCHLORIDE ingredient
NCE-1 date: 21 March, 2028
Market Authorisation Date: 21 March, 2024
Dosage: SUSPENSION
More Information on Dosage
DUVYZAT family patents
4. Exondys 51 patent expiration
Treatment: (i)treatment of duchenne muscular dystrophy; (ii)restoring/increasing functional dystrophin protein; Or (iii) inducing skipping; Each of (i)...
EXONDYS 51's oppositions filed in EPO
EXONDYS 51 IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9416361 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US9243245 | SAREPTA THERAPS INC | Means and methods for counteracting muscle disorders |
Oct, 2028
(2 years from now) | |
| US9018368 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US10781451 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8486907 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US10533174 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US10364431 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(8 years from now) | |
| USRE47751 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US9506058 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(8 years from now) | |
| US10337003 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(8 years from now) | |
| USRE48468 | SAREPTA THERAPS INC | Means and methods for counteracting muscle disorders |
Oct, 2028
(2 years from now) | |
| USRE47769 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Sep 19, 2023 |
| Orphan Drug Exclusivity(ODE-122) | Sep 19, 2023 |
Drugs and Companies using ETEPLIRSEN ingredient
NCE-1 date: 19 September, 2020
Market Authorisation Date: 19 September, 2016
Dosage: SOLUTION
More Information on Dosage
EXONDYS 51 family patents
5. Viltepso patent expiration
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skippin...
VILTEPSO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10870676 | NIPPON SHINYAKU | Antisense nucleic acids |
Aug, 2031
(5 years from now) | |
| US9079934 | NIPPON SHINYAKU | Antisense nucleic acids |
Apr, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2025 |
| Orphan Drug Exclusivity(ODE-280) | Aug 12, 2027 |
Drugs and Companies using VILTOLARSEN ingredient
NCE-1 date: 12 August, 2024
Market Authorisation Date: 12 August, 2020
Dosage: SOLUTION
More Information on Dosage
VILTEPSO family patents
6. Vyondys 53 patent expiration
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping
VYONDYS 53's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9416361 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US10227590 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US9024007 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US10421966 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US9994851 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US10968450 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10533174 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US10266827 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US10995337 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| USRE47691 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2024 |
| Orphan Drug Exclusivity(ODE-280) | Dec 12, 2026 |
Drugs and Companies using GOLODIRSEN ingredient
NCE-1 date: 13 December, 2023
Market Authorisation Date: 12 December, 2019
Dosage: SOLUTION
More Information on Dosage
VYONDYS 53 family patents